Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Interferon beta-1a (Rebif)

**Notes:**
* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

**Initiation (new start) criteria:** Non-formulary interferon beta-1a (Rebif) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Neurologist
- Diagnosis of Relapsing form of Multiple Sclerosis (MS) on the Problem list, including:
  - Non-Progressive Relapsing MS
  - Progressive Relapsing MS
  - Relapsing Remitting MS
- Patient has an allergy or is intolerance* to
  - Glatiramer acetate (Copaxone or Glatopa) **AND**
  - Interferon-beta1b (Extavia)

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary interferon beta-1a (Rebif) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Neurologist
- Diagnosis of Multiple Sclerosis (MS) on the Problem list
- Patient has an allergy or is intolerance* to
  - Glatiramer acetate (Copaxone or Glatopa) **AND**
  - Interferon-beta1b (Extavia)

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously.** Non-formulary interferon beta-1a (Rebif) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Diagnosis of Multiple Sclerosis (MS)
- Patient has an allergy or is intolerance* to
  - Glatiramer acetate (Copaxone or Glatopa) **AND**
  - Interferon-beta1b (Extavia)
**Criteria-Based Consultation Prescribing Program**

**CRITERIA FOR DRUG COVERAGE**

**Interferon beta-1a (Rebif)**

**Continued use criteria (after initiation):** Non-formulary interferon beta-1a (Rebif) will continue to be covered on the prescription drug benefit when the following criteria are met:

- Not applicable

**Continued use criteria for patients stable on the medication:** Non-formulary interferon beta-1a (Rebif) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Neurologist
- Patient has completed the following labs within the last 6 months:
  - Complete blood count with differential (CBC w/ diff)
  - Liver function test (alanine aminotransferase, ALT)
- Patient is NOT using interferon beta-1a (Rebif) with another disease modifying treatment (i.e., glatiramer, interferon beta-1b, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, rituximab)